Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC007g in Post-allo-HSCT Relapsed/Refractory CD19+ B-ALL
CTR20213017Phase 2Terminated
- Sponsor
- GenScript
- Start
- Dec 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GC007g in B cell acute lymphoblastic leukemia (B-ALL), sponsored by GenScript. Started Dec 2021; status: terminated.
02
Drugs
GC007g
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20213017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213017.